Adjunctive Therapy

In a 52-week adjunctive therapy trial, RISPERDAL^® CONSTA^® when added to lithium or valproate significantly delayed time to relapse vs placebo plus lithium or valproate (P=0.01)³
The study also demonstrated that significantly fewer patients relapsed during treatment with RISPERDAL^® CONSTA^® plus lithium or valproate compared to placebo plus lithium or valproate (23.1% vs 45.8%)³

Percentage of patients who relapsed over a 52-week period³

Chart

Demonstrated in a 52-week, multicenter, randomized, double-blind, placebo-controlled study in 124 patients with Bipolar I Disorder ¹
Doses of 25, 37.5, or 50 mg were given by intramuscular injection every 2 weeks, in addition to their individually defined adjunctive treatment, which consisted of mood stabilizers (primarily lithium and valproate), antidepressants, and/or anxiolytics
All other antipsychotics were discontinued after the first 3 weeks of the initial injection
Patients who were judged to be stable for at least the last 4 weeks of a 16-week, open-label phase were randomized in the double-blind phase
The primary endpoint was time to relapse to any new mood episode

Monotherapy

Print this page

Details on
RISPERDAL^® CONSTA^® access and reimbursement at CONSTANTResource.com

Access the Ortho-McNeil Janssen Scientific Affairs Medical Communications Database

Tell a Colleague

Know someone who risperdalconsta.com could help?

Share Now

Tell a Colleague

RISPERDAL^® CONSTA^® (risperidone) long-acting injection is indicated for the treatment of schizophrenia and the maintenance treatment of Bipolar I Disorder .

IMPORTANT SAFETY INFORMATION FOR RISPERDAL^® CONSTA^®

WARNING: Increased Mortality in Elderly Patients with Dementia-Related Psychosis

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in the drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. RISPERDAL^® CONSTA^® (risperidone) is not approved for the treatment of patients with dementia-related psychosis.

Contraindications: RISPERDAL^® CONSTA^® is contraindicated in patients with a known hypersensitivity to the product.
Cerebrovascular Adverse Events (CAEs): CAEs (e.g., stroke, transient ischemia attacks), including fatalities, were reported in placebo-controlled trials in elderly patients with dementiarelated psychosis taking oral risperidone. The incidence of CAEs was significantly higher than with placebo. RISPERDAL^® CONSTA^® is not approved for the treatment of patients with dementia-related psychosis.
Neuroleptic Malignant Syndrome (NMS): NMS, a potentially fatal symptom complex, has been reported with the use of antipsychotic medications, including RISPERDAL^® CONSTA^® . Clinical manifestations include muscle rigidity, fever, altered mental status and evidence of autonomic instability (see full Prescribing Information). Management should include immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy, intensive symptomatic treatment and medical monitoring, and treatment of any concomitant serious medical problems.
Tardive Dyskinesia (TD): TD is a syndrome of potentially irreversible, involuntary, dyskinetic movements that may develop in patients treated with antipsychotic medications. The risk of developing TD and the likelihood that dyskinetic movements will become irreversible are believed to increase with duration of treatment and total cumulative dose, but can develop after relatively brief treatment at low doses. Elderly women patients appeared to be at increased risk for TD, although it is impossible to predict which patients will develop the syndrome. Prescribing should be consistent with the need to minimize the risk of TD (see full Prescribing Information). Discontinue drug if clinically appropriate. The syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn.
Hyperglycemia and Diabetes: Hyperglycemia, some cases extreme and associated with ketoacidosis, hyperosmolar coma or death has been reported in patients treated with atypical antipsychotics (APS), including RISPERDAL^®. Patients starting treatment with APS who have or are at risk for diabetes mellitus should undergo fasting blood glucose testing at the beginning of and during treatment. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing. All patients treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia. Some patients require continuation of anti-diabetic treatment despite discontinuation of the suspect drug.
Hyperprolactinemia: As with other drugs that antagonize dopamine D₂ receptors, RISPERDAL^® CONSTA^® elevates prolactin levels and the elevation persists during chronic administration. Risperidone is associated with higher levels of prolactin elevation than other antipsychotic agents.
Orthostatic Hypotension: RISPERDAL^® CONSTA^® may induce orthostatic hypotension associated with dizziness, tachycardia, and in some patients, syncope, especially during the initial dose-titration period. RISPERDAL^® CONSTA^® should be used with caution in patients with known cardiovascular disease (e.g., heart failure, history of MI or ischemia, conduction abnormalities), cerebrovascular disease or conditions that would predispose patients to hypotension (e.g., dehydration, hypovolemia) and additionally elderly patients and with renal or hepatic impairment. Monitoring should be considered in patients for whom this may be of concern.
Leukopenia, Neutropenia and Agranulocytosis have been reported with antipsychotics, including RISPERDAL^® CONSTA^® . Patients with a history of clinically significant low white blood cell count (WBC) or drug-induced leukopenia/neutropenia should have frequent complete blood cell counts during the first few months of therapy. At the first sign of a clinically significant decline in WBC, and in the absence of other causative factors, discontinuation of RISPERDAL^® CONSTA^® should be considered. Patients with clinically significant neutropenia should be carefully monitored for fever or other symptoms or signs of infection and treated promptly if such symptoms or signs occur. Patients with severe neutropenia (absolute neutrophil count <1000/mm³) should discontinue RISPERDAL^® CONSTA^® and have their WBC followed until recovery.
Potential for Cognitive and Motor Impairment: Somnolence was reported in multiple trials in subjects treated with RISPERDAL^® CONSTA^® . Since RISPERDAL^® CONSTA^® has the potential to impair judgment, thinking, or motor skills, patients should be cautioned about operating hazardous machinery, including motor vehicles, until they are reasonably certain that RISPERDAL^® CONSTA^® does not adversely affect them.
Seizures: RISPERDAL^® CONSTA^® should be used cautiously in patients with a history of seizures.
Dysphagia: Esophageal dysmotility and aspiration have been associated with antipsychotic drug use. Aspiration pneumonia is a common cause of morbidity and mortality in patients with advanced Alzheimer’s dementia. Use cautiously in patients at risk for aspiration pneumonia.
Priapism has been reported. Severe priapism may require surgical intervention.
Thrombotic Thrombocytopenic Purpura (TTP) has been reported.
Administration: For intramuscular injection only. Care should be taken to avoid inadvertent injection into a blood vessel.
Suicide: The possibility of suicide attempt is inherent in schizophrenia or bipolar disorder. Close supervision of high-risk patients should accompany drug therapy.
Increased sensitivity in patients with Parkinson’s disease or those with dementia with Lewy bodies has been reported. Manifestations and features are consistent with NMS.
Use RISPERDAL^® CONSTA^® with caution in patients with conditions and medical conditions that could affect metabolism or hemodynamic responses (e.g. recent myocardial infarction or unstable cardiac disease).
SCHIZOPHRENIA ONLY: Commonly Observed Adverse Reactions for RISPERDAL^® CONSTA^® : The most common adverse reactions in clinical trials in patients with schizophrenia (≥5%) were headache, Parkinsonism, dizziness, akathisia, fatigue, constipation, dyspepsia, sedation, weight increase, pain in extremities, and dry mouth.
BIPOLAR ONLY: Commonly Observed Adverse Reactions for RISPERDAL^® CONSTA^® : The most common adverse reactions in clinical trials in patients with bipolar disorder were weight increased (5% in monotherapy trial) and tremor and Parkinsonism (≥10% in adjunctive therapy trial).
SCHIZOPHRENIA/BIPOLAR COMBO: Commonly Observed Adverse Reactions for RISPERDAL^® CONSTA^® : The most common adverse reactions in clinical trials in patients with schizophrenia (≥5%) were headache, Parkinsonism, dizziness, akathisia, fatigue, constipation, dyspepsia, sedation, weight increase, pain in extremities, and dry mouth. The most common adverse reactions in clinical trials in patients with bipolar disorder were weight increased (5% in monotherapy trial) and tremor and Parkinsonism (≥10% in adjunctive therapy trial).

For more information about RISPERDAL^® CONSTA^® , please read the full U.S. Prescribing Information.

Your use of the information on this site is subject to the terms of our Legal Notice. Please see our Privacy Policy.

This site is published by Janssen^®, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., which is solely responsible for its contents. This information is intended for the use of our customers, patients, and healthcare professionals in the United States only. Janssen^®, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. recognizes that the Internet is a global communications medium; however, laws, regulatory requirements, and medical practices for pharmaceutical products vary from country to country. The Prescribing Information included here may not be appropriate for use outside the United States.

Capitalized product names are trademarks of Ortho-McNeil-Janssen Pharmaceuticals, Inc.

Some documents on this site are stored in Adobe PDF format and require the free Adobe^® Reader^® to view.